Cell-specific responses to loss of cyclin-dependent kinases

Oncogene

Volumn 26, Issue 31, 2007, Pages 4469-4477

  Berthet, C ^a   Kaldis, P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cell cycle; Cyclin; Cyclin dependent kinase; Differentiated cells; Embryonic stem cells; Tumor cells

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLINE;

APOPTOSIS; CANCER THERAPY; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TYPE; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SENESCENCE; SENSITIVITY ANALYSIS; STEM CELL; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL DEATH; CELL DIFFERENTIATION; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; CYCLINS; EMBRYONIC STEM CELLS; GENE SILENCING; MICE; MUTATION; NEOPLASMS; SIGNAL TRANSDUCTION;

MUS;

EID: 34447119665     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210243     Document Type: Review

References (81)

1. Aladjem MI, Spike BT, Rodewald LW, Hope TJ, Klemm M, Jaenisch R et al. (1998). ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage. Curr Biol 8: 145-155.
2. Aleem E, Kaldis P. (2006). Mouse models of cell cycle regulators: new paradigms. Results Probl Cell Differ 42: 271-328.
3. Aleem E, Kiyokawa H, Kaldis P. (2005). Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat Cell Biol 7: 831-836.
4. Appert-Collin A, Hugel B, Levy R, Niederhoffer N, Coupin G, Lombard Y et al. (2006). Cyclin-dependent kinase inhibitors prevent apoptosis of postmitotic mouse motoneurons. Life Sci 79: 484-490.
5. Arber N, Doki Y, Han EK, Sgambato A, Zhou P, Kim NH et al. (1997). Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 57: 1569-1574.
6. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P. (2003). Cdk2 knockout mice are viable. Curr Biol 13: 1775-1785.
7. Berthet C, Kaldis P. (2006). Cdk2 and Cdk4 cooperatively control the expression of Cdc2. Cell Div 1: 10.
8. Berthet C, Klarmann KD, Hilton MB, Suh HC, Keller JR, Kiyokawa H et al. (2006). Combined loss of Cdk2 and Cdk4 results in embryonic lethality and Rb hypophosphorylation. Dev Cell 10: 563-573.
9. Bertram MJ, Berube NG, Hang-Swanson X, Ran Q, Leung JK, Bryce S et al. (1999). Identification of a gene that reverses the immortal phenotype of a subset of cells and is a member of a novel family of transcription factor-like genes. Mol Cell Biol 19: 1479-1485.
10. Blasco MA. (2005). Mice with bad ends: mouse models for the study of telomeres and telomerase in cancer and aging. EMBO J 24: 1095-1103.
11. Brandeis M, Rosewell I, Carrington M, Crompton T, Jacobs AM, Kirk J et al. (1998). Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die in utero. Proc Natl Acad Sci USA 95: 4344-4349.
12. Burdon T, Smith A, Savatier P. (2002). Signalling, cell cycle and pluripotency in embryonic stem cells. Trends Cell Biol 12: 432-438.
13. Cai D, Latham Jr VM, Zhang X, Shapiro GI. (2006). Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 66: 9270-9280.
14. Campisi J. (2005). Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120: 513-522.
15. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M et al. (2005). Tumour biology: senescence in premalignant tumours. Nature 436: 642.
16. Dannenberg JH, van Rossum A, Schuijff L, te Riele H. (2000). Ablation of the retinoblastoma gene family deregulates G1 control causing immortalization and increased cell turnover under growth-restricting conditions. Genes Dev 14: 3051-3064.
17. Dimri GP. (2005). What has senescence got to do with cancer? Cancer Cell 7: 505-512.
18. Du L, Lyle CS, Obey TB, Gaarde WA, Muir JA, Bennett BL et al. (2004). Inhibition of cell proliferation and cell cycle progression by specific inhibition of basal JNK activity: evidence that mitotic Bcl-2 phosphorylation is JNK-independent. J Biol Chem 279: 11957-11966.
19. Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C. (1995). Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev 9: 2364-2372.
20. Kip1-deficient mice. Cell 85: 733-744.
21. Furuno N, den Elzen N, Pines J. (1999). Human cyclin A is required for mitosis until mid prophase. J Cell Biol 147: 295-306.
22. Geng Y, Yu Q, Sicinska E, Das M, Schneider JE, Bhattacharya S et al. (2003). Cyclin E ablation in the mouse. Cell 114: 431-443.
23. Gil-Gomez G, Berns A, Brady HJ. (1998). A link between cell cycle and cell death: Bax and Bcl-2 modulate Cdk2 activation during thymocyte apoptosis. EMBO J 17: 7209-7218.
24. Hakem A, Sasaki T, Kozieradzki I, Penninger JM. (1999). The cyclin-dependent kinase Cdk2 regulates thymocyte apoptosis. J Exp Med 189: 957-968.
25. Jirmanova L, Afanassieff M, Gobert-Gosse S, Markossian S, Savatier P. (2002). Differential contributions of ERK and PI3-kinase to the regulation of cyclin D1 expression and to the control of the G1/S transition in mouse embryonic stem cells. Oncogene 21: 5515-5528.
26. ARF. Cell 91: 649-659.
27. Kiyokawa H. (2006). Senescence and cell cycle control. Results Probl Cell Differ 42: 257-270.
28. Kip1. Cell 85: 721-732.
29. Knudsen ES, Knudsen KE. (2006). Retinoblastoma tumor suppressor: where cancer meets the cell cycle. Exp Biol Med 231: 1271-1281.
30. Kornmann M, Arber N, Korc M. (1998). Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 101: 344-352.
31. Kozar K, Ciemerych MA, Rebel VI, Shigematsu H, Zagozdzon A, Sicinska E et al. (2004). Mouse development and cell proliferation in the absence of D-cyclins. Cell 118: 477-491.
32. Landis MW, Pawlyk BS, Li T, Sicinski P, Hinds PW. (2006). Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 9: 13-22.
33. Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G et al. (2000). Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol 20: 672-683.
34. Li L, Zou L. (2005). Sensing, signaling, and responding to DNA damage: organization of the checkpoint pathways in mammalian cells. J Cell Biochem 94: 298-306.
35. Malumbres M, Sotillo R, Santamaria D, Galan J, Cerezo A, Ortega S et al. (2004). Mammalian cells cycle without the Dtype cyclin-dependent kinases Cdk4 and Cdk6. Cell 118: 493-504.
36. Cip1. Cancer Cell 7: 591-598.
37. Meikrantz W, Gisselbrecht S, Tam SW, Schlegel R. (1994). Activation of cyclin A-dependent protein kinases during apoptosis. Proc Natl Acad Sci USA 91: 3754-3758.
38. Miliani de Marval PL, Macias E, Rounbehler R, Sicinski P, Kiyokawa H, Johnson DG et al. (2004). Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues. Mol Cell Biol 24: 7538-7547.
39. Mittnacht S. (1998). Control of pRB phosphorylation. Current Opinion in Genetics & Development 8: 21-27.
40. Miura T, Mattson MP, Rao MS. (2004). Cellular lifespan and senescence signaling in embryonic stem cells. Aging Cell 3: 333-343.
41. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G et al. (2006). A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124: 1283-1298.
42. Monaco III EA, Vallano ML. (2003). Cyclin-dependent kinase inhibitors: cancer killers to neuronal guardians. Curr Med Chem 10: 367-379.
43. Morgan DO. (1997). Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13: 261-291.
44. Muller-Tidow C, Ji P, Diederichs S, Potratz J, Baumer N, Kohler G et al. (2004). The cyclin A1-CDK2 complex regulates DNA double-strand break repair. Mol Cell Biol 24: 8917-8928.
45. Murphy M, Stinnakre M-G, Senamaud-Beaufort C, Winston NJ, Sweeney C, Kubelka M et al. (1997). Delayed early embryonic lethality following disruption of the murine cyclin A2 gene. Nat Genet 15: 83-86.
46. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85: 707-720.
47. Ortega S, Prieto I, Odajima J, Martin A, Dubus P, Sotillo R et al. (2003). Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 35: 25-31.
48. Pagano M, Jackson PK. (2004). Wagging the dogma; tissuespecific cell cycle control in the mouse embryo. Cell 118: 535-538.
49. Parisi T, Beck AR, Rougier N, McNeil T, Lucian L, Werb Z et al. (2003). Cyclins E1 and E2 are required for endoreplication in placental trophoblast giant cells. EMBO J 22: 4794-4803.
50. Payton M, Chung G, Yakowec P, Wong A, Powers D, Xiong L et al. (2006). Discovery and evaluation of dual CDK1 and CDK2 inhibitors. Cancer Res 66: 4299-4308.
51. Ink4c on Cdk4. Mol Cell Biol 24: 6653-6664.
52. Price PM, Yu F, Kaldis P, Aleem E, Nowak G, Safirstein RL et al. (2006). Dependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2. J Am Soc Nephrol 17: 2434-2442.
53. Prost S, Bellamy CO, Clarke AR, Wyllie AH, Harrison DJ. (1998). p53-independent DNA repair and cell cycle arrest in embryonic stem cells. FEBS Lett 425: 499-504.
54. Rane SG, Dubus P, Mettus RV, Galbreath EJ, Boden G, Reddy EP et al. (1999). Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in b-islet cell hyperplasia. Nat Genet 22: 44-52.
55. Reddy HK, Mettus RV, Rane SG, Grana X, Litvin J, Reddy EP. (2005). Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. Cancer Res 65: 10174-10178.
56. Ribas J, Boix J, Meijer L. (2006). (R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis. Exp Cell Res 312: 2394-2400.
57. Robles AI, Rodriguez-Puebla ML, Glick AB, Trempus C, Hansen L, Sicinski P et al. (1998). Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev 12: 2469-2474.
58. Rodriguez-Puebla ML, Miliani de Marval PL, LaCava M, Moons DS, Kiyokawa H, Conti CJ. (2002). Cdk4 deficiency inhibits skin tumor development but does not affect normal keratinocyte proliferation. Am J Pathol 161: 405-411.
59. Rossi AG, Sawatzky DA, Walker A, Ward C, Sheldrake TA, Riley NA et al. (2006). Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med 12: 1056-1064.
60. Rouault JP, Falette N, Guehenneux F, Guillot C, Rimokh R, Wang Q et al. (1996). Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet 14: 482-486.
61. Sage J, Mulligan GJ, Attardi LD, Miller A, Chen S, Williams B et al. (2000). Targeted disruption of the three Rb-related genes leads to loss of G1 control and immortalization. Genes Dev 14: 3037-3050.
62. Santamaria D, Ortega S. (2006). Cyclins and CDKs in development and cancer: lessons from genetically modified mice. Front Biosci 11: 1164-1188.
63. Sauter ER, Nesbit M, Litwin S, Klein-Szanto AJ, Cheffetz S, Herlyn M. (1999). Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res 59: 4876-4881.
64. Savatier P, Huang S, Szekely L, Wiman KG, Samarut J. (1994). Contrasting patterns of retinoblastoma protein expression in mouse embryonic stem cells and embryonic fibroblasts. Oncogene 9: 809-818.
65. Savatier P, Lapillonne H, van Grunsven LA, Rudkin BB, Samarut J. (1996). Withdrawal of differentiation inhibitory activity/leukemia inhibitory factor up-regulates D-type cyclins and cyclin-dependent kinase inhibitors in mouse embryonic stem cells. Oncogene 12: 309-322.
66. Arf predisposes mice to tumorigenesis. Nature 413: 86-91.
67. Sherr CJ, Roberts JM. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512.
68. Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H et al. (1995). Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82: 621-630.
69. Stanelle J, Putzer BM. (2006). E2F1-induced apoptosis: turning killers into therapeutics. Trends Mol Med 12: 177-185.
70. Stead E, White J, Faast R, Conn S, Goldstone S, Rathjen J et al. (2002). Pluripotent cell division cycles are driven by ectopic Cdk2, cyclin A/E and E2F activities. Oncogene 21: 8320-8333.
71. Tetsu O, McCormick F. (2003). Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 3: 233-245.
72. Kip1 activity. Mol Cell Biol 19: 7011-7019.
73. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H et al. (2002). p53 mutant mice that display early ageing-associated phenotypes. Nature 415: 45-53.
74. Vousden KH, Lu X. (2002). Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604.
75. Wadhwa R, Kaul SC, Mitsui Y. (1994). Cellular mortality to immortalization: mortalin. Cell Struct Funct 19: 1-10.
76. Wesierska-Gadek J, Schreiner T, Gueorguieva M, Ranftler C. (2006). Phenol red reduces ROSC-mediated cell cycle arrest and apoptosis in human MCF-7 cells. J Cell Biochem 98: 1367-1379.
77. Williams O, Gil-Gomez G, Norton T, Kioussis D, Brady HJ. (2000). Activation of Cdk2 is a requirement for antigenmediated thymic negative selection. Eur J Immunol 30: 709-713.
78. Yu Q, Geng Y, Sicinski P. (2001). Specific protection against breast cancers by cyclin D1 ablation. Nature 411: 1017-1021.
79. Yu Q, Sicinska E, Geng Y, Ahnstrom M, Zagozdzon A, Kong Y et al. (2006). Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9: 23-32.
80. Zhou P, Jiang W, Zhang YJ, Kahn SM, Schieren I, Santella RM et al. (1995). Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene 11: 571-580.
81. Zou X, Ray D, Aziyu A, Christov K, Boiko AD, Gudkov AV et al. (2002). Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev 16: 2923-2934.